“I would also like to thank David Riggs, who has served as our CFO since
2013, for all of his contributions. David was instrumental in Eagle’s
IPO and growing the Company to where it is today. We look forward to his
continued engagement with the Company”

Pete A. Meyers has over two decades of experience in the health care
industry. He most recently served as Chief Financial Officer of Motif
BioSciences Inc., from May 2016 to January 2017. Prior to his role at
Motif, he served as Chief Financial Officer and Treasurer of TetraLogic
Pharmaceuticals Corporation from August 2013 to March 2016. Mr. Meyers
also spent 18 years as a health care investment banker, most recently as
Co-Head of Global Health Care Investment Banking at Deutsche Bank
Securities Inc. Mr. Meyers currently serves on the Board of Directors of
Prima BioMed Ltd, where he chairs the Audit Committee.

“Pete’s extensive operations experience in the biopharma sector will
provide invaluable insight and guidance as we seek to expand our
commercialization strategy to include our first product marketed
exclusively by Eagle’s internal sales organization, Ryanodex®
(dantrolene sodium) for the treatment of exertional heat stroke, if
approved. Pete’s expertise will complement the capabilities of our
senior management team, and we look forward to working with him on this
and other projects,” stated Scott Tarriff, Chief Executive Officer of
Eagle Pharmaceuticals.

“I would also like to thank David Riggs, who has served as our CFO since
2013, for all of his contributions. David was instrumental in Eagle’s
IPO and growing the Company to where it is today. We look forward to his
continued engagement with the Company,” added Tarriff.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and
commercializing injectable products that address the shortcomings, as
identified by physicians, pharmacists and other stakeholders, of
existing commercially successful injectable products. Eagle’s strategy
is to utilize the FDA's 505(b)(2) regulatory pathway. Additional
information is available on the company’s website at www.eagleus.com.

Forward-Looking Statements

This press release contains forward-looking information within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended and other securities laws. Forward-looking statements are
statements that are not historical facts. Words such as “will,” “may,”,
“believe,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,”
“entitles,” “provide,” “complement,” “seek,” “expand” and similar
expressions are intended to identify forward-looking statements. These
statements include statements regarding future events including, but not
limited to: the timing, if at all, of the approval by the FDA of an
exertional heat stroke indication for Eagle’s Ryanodex; the likelihood
that any changes to Eagle’s management team will affect the ability of
Eagle to deliver sustained stockholder value over time; and other
factors that are discussed in Eagle’s Annual Report on Form 10-K for the
year ended December 31, 2016, and its other filings with the U.S.
Securities and Exchange Commission. All of such statements are subject
to certain risks and uncertainties, many of which are difficult to
predict and generally beyond Eagle’s control, that could cause actual
results to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. Such risks
include, but are not limited to whether Eagle’s management and/or board
of directors will be effective in managing Eagle’s business and future
growth, as well as the other risks described in Eagle’s filings with the
U.S. Securities and Exchange Commission. Readers are cautioned not to
place undue reliance on these forward-looking statements that speak only
as of the date hereof, and we do not undertake any obligation to revise
and disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of or
non-occurrence of any events.